Contact us
Craig Marks | Adrien Dupin de Saint-Cyr |
Vice President, Investor Relations | Investor Relations Manager |
+44 7584 349 193 | +33 6 64 26 17 49 |
Contact us
Ipsen to acquire Epizyme, expanding its portfolio in oncology
Conference call
A conference call and webcast for investors and analysts will begin today at 2pm Paris time.
Participants can join the call by dialling +1 785 424 1876 or, for U.S. participants, +1 877 888 4312 toll-free;
the passcode is 63710.
Ipsen to acquire Epizyme, expanding its portfolio in oncology
Ipsen in Brief
Ipsen in Brief 2022
Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.
DownloadRegistration document
2021 Universal Registration Document
This registration document contains forward-looking statements about Ipsen’s targets and forecasts, including the Annual Financial Report. The registration document provides a comprehensive information about the Company its activities, financial information, colleagues and legal information
DownloadResearch & Development pipeline
Ipsen R&D has a valuable pipeline encompassing both lifecycle management of our well-established products, and the development of innovative new molecules.
Learn more